期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型口服抗凝药在急性冠脉综合征中的应用 被引量：7

下载PDF
导出
摘要 血栓形成在急性冠脉综合征(ACS)发生、发展过程中起着重要作用。目前,作用于凝血连锁反应不同水平的新型抗凝药物已被研究并应用于预防深静脉血栓、房颤卒中以及ACS患者二级预防,特别是口服直接凝血酶抑制剂(希美加群、达比加群,AZD0837)以及口服直接Xa抑制剂(阿哌沙班、利伐沙班、darexaban、edoxaban、betrixaban等)是目前公认比华法林更安全、便捷的替代品。达比加群、阿哌沙班、利伐沙班、darexaban已在ACS患者中进行临床试验。
作者 金厦 殷跃辉
机构地区 重庆医科大学第二附属医院心内科
出处 《国际心血管病杂志》 2013年第1期34-37,共4页 International Journal of Cardiovascular Disease
关键词 急性冠脉综合征 口服抗凝药物 利伐沙班 达比加群 阿哌沙班
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献24

  • 1Wright R S,Anderson J L,Adams C D. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians,Society for Cardiovascular Angiography an[J].Journal of the American College of Cardiology,2011,(19):e215-e367. 被引量：1
  • 2Kushner F G,Hand M,Jr Smith S C. 2009 focused updates:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideli[J].Journal of the American College of Cardiology,2009,(23):2205-2241. 被引量：1
  • 3Wiggins N B,Granger C B,Alexander J H. Novel Oral Anticoagulants After Acute Coronary Syndromes[J].Cardiovascular Drugs and Therapy,2012,(03):265-271. 被引量：1
  • 4Ahmed S,Levin V,Malacoff R. Dabigatran:a new chapter in anticoagulation[J].Cardiovasc Hematol Agents Med Chem,2012,(02):116-123. 被引量：1
  • 5Oldgren J,Budaj A,Granger C B. Dabigatran vs.placebo in patients with acute coronary syndromes on dual antiplatelet therapy:a randomized,double blind,phase Ⅱ trial[J].European Heart Journal,2011,(22):2781-2789. 被引量：1
  • 6Tangelder M J,Frison L,Weaver D. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial[J].American Heart Journal,2008,(02):382-387. 被引量：1
  • 7Keisu M,Andersson T B. Drug-induced liver injury in humans:the case of ximelagatran[J].Handbook of Experimental Pharmacology,2010,(196):407-418. 被引量：1
  • 8Lip G Y,Rasmussen L H,Olsson S B. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation:a Phase Ⅱ study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy[J].Thrombosis Research,2011,(02):91-99. 被引量：1
  • 9Romualdi E,Ageno W. Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes[J].Handbook of Experimental Pharmacology,2010,(196):407-418. 被引量：1
  • 10Gassanov N,Caglayan E,Er F. Apixaban:pharmacology and action profile[J].Deutsche Medizinische Wochenschrift,2012,(04):138-141. 被引量：1

同被引文献74

  • 1张静.低分子肝素治疗急性冠脉综合征的观察与护理[J].求医问药（下半月）,2013(7):277-277. 被引量：3
  • 2Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J].N Engl J Med,2001,345 (7):494-502. 被引量：1
  • 3Wiviott SD,Braunwald E,McCabe CH,et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2007,357(20):2001-2015. 被引量：1
  • 4Wallentin L,Becker RC,Budaj A,el al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057. 被引量：1
  • 5Morrow DA,Braunwald E,Bonaca MP,et al.Vorapaxar in the secondary prevention of atherothrombotic events[J].N Engl J Med,2012,366(15):1404-1413. 被引量：1
  • 6Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J].Eur Heart J,2011,32(23):2999-3054. 被引量：1
  • 7Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators,Yusuf S,Mehta SR,et al.Comparison of fondaparinux and enoxaparin in acute coronary syndromes[J].N Engl J Med,2006,354(14):1464-1476. 被引量：1
  • 8APPRAISE Steering Committee and Investigators1,Alexander JH,Becker RC,et al.Apixaban,an oral,direct,selective factor Xa inhibitor,in combination with antiplatelet therapy after acute coronary syndrome:results of the Apixaban for Prevention of Acute Ischemic and Safety Events(APPRAISE) trial[J].Circulation,2009,119(22):2877-2885. 被引量：1
  • 9Steg PG,Mehta SR,Jukema JW,et al.RUBY-1:a randomized,doubleblind,placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome[J].Eur Heart J,2011,32 (20):2541-2554. 被引量：1
  • 10Ahmed-S,Levin-V,Malacoff-R,et al.Dabigatran:a-new-chapter-in-anticoagulation[J].Cardiovasc Hematol Agents Med Chem,2012,10 (2):116-123. 被引量：1

引证文献7

二级引证文献52

国际心血管病杂志
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部